- Home
- QUCY vs NSPR Comparison
QUCY vs NSPR Comparison
Compare QUCY & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | NSPR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | Germany | United States |
| Employees | 13 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 33.7M |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | QUCY | NSPR |
|---|---|---|
| Price | $1.45 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 3.2M | 121.6K |
| Earning Date | 06-26-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $74.34 | $57.98 |
| Revenue Next Year | $171.48 | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.63 |
| 52 Week High | $4.93 | $2.93 |
Technical Indicators
Market Signals| Indicator | QUCY | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 37.02 |
| Support Level | $1.38 | $0.69 |
| Resistance Level | $2.36 | $1.04 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 7.61 | 26.74 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity. It aims to secure critical infrastructure and data against these emerging threats.
About NSPR InspireMD Inc.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.